Pharma channel feed

A 'chilling,' 'oner­ous' and 'his­toric mis­take': Phar­ma CEOs take their turn blast­ing drug pric­ing deal

3 years ago

Mar­ket­ingRx roundup: Bio­haven study links mi­graine and men­tal health; B+L bows Tik­Tok chal­lenge

3 years ago
Marketing

Gran­flu­encers and boom­flu­encers: Is the hip­ster old­ster so­cial me­dia trend mov­ing to phar­ma?

3 years ago
Marketing

How do you put a pos­i­tive spin on ug­ly da­ta? AC Im­mune gives it a shot in the wake of the lat­est crenezum­ab flop

3 years ago
Bioregnum

Af­ter FDA re­quests a new tri­al, Al­lar­i­ty drops a can­cer drug from so­lo de­vel­op­ment

3 years ago
R&D

Roche wins an edge in the hy­per­com­pet­i­tive race for PD-(L)1 mar­ket share

3 years ago
R&D

Un­der pres­sure from ad­vo­cates, Vi­iV strikes a deal to make its long-act­ing HIV in­jectable more ac­ces­si­ble

3 years ago
Deals

Bio­gen's new SMA aware­ness cam­paign in Spain spot­lights the 'in­vis­i­ble' care­givers

3 years ago
Marketing

J&J nabs la­bel ex­pan­sion for Ste­lara in pe­di­atric pso­ri­at­ic arthri­tis

3 years ago
FDA+

Space, the fi­nal fron­tier for drug man­u­fac­tur­ing?

3 years ago
Manufacturing

Ab­b­Vie's Al­ler­gan inks $2.3B+ opi­oid set­tle­ment with sev­er­al states

3 years ago
Law

Bausch Health as­serts push to 'vig­or­ous­ly' de­fend Xi­fax­an patent lit­i­ga­tion 

3 years ago
Law

Re­gen­eron ends four clin­i­cal tri­als of its rolled-back Covid-19 an­ti­body

3 years ago
R&D
Coronavirus

Ar­cutis pulls in a win for its top­i­cal ver­sion of an old As­traZeneca drug in plaque pso­ri­a­sis

3 years ago
FDA+

Ab­b­Vie, No­vo Nordisk TV ads gen­er­ate most search­es in first half of 2022, ad track­er finds

3 years ago
Marketing

CEO Pas­cal So­ri­ot says As­traZeneca is grow­ing 'new branch­es' as Covid vac­cine sales con­tin­ue to fall

3 years ago

JA­MA study finds can­cer drug da­ta is still large­ly un­avail­able to qual­i­fied re­searchers

3 years ago

Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

3 years ago
Law

Ab­b­Vie stays bull­ish on fu­ture per­for­mance as Skyrizi con­tin­ues to im­press — but 'price con­trol­s' would be a game chang­er

3 years ago

Trans­plant Games kick off in San Diego, rais­ing or­gan do­na­tion aware­ness, com­mu­ni­ty and hope

3 years ago
Marketing

Bris­tol My­er­s' com­bo hits a road­block in PhI­II kid­ney test as the search to ri­val Keytru­da con­tin­ues

3 years ago
R&D

Af­ter near­ly a decade of work, As­traZeneca ax­es WEE1 and culls Mod­er­na-part­nered drug

3 years ago
R&D

Seagen stays qui­et on M&A as it push­es Keytru­da-Pad­cev com­bo, con­tin­ues CEO search

3 years ago

Dana-Far­ber CEO Lau­rie Glim­ch­er re­signs from GSK board — is she the next NIH di­rec­tor nom­i­nee?

3 years ago
People
First page Previous page 183184185186187188189 Next page Last page
A service from the Financial Times